MARKET

OMER

OMER

Omeros
NASDAQ
3.795
-2.385
-38.59%
Pre Market: 3.750 -0.045 -1.19% 04:05 05/13 EDT
OPEN
5.87
PREV CLOSE
6.18
HIGH
5.90
LOW
3.790
VOLUME
10
TURNOVER
--
52 WEEK HIGH
13.60
52 WEEK LOW
3.000
MARKET CAP
221.27M
P/E (TTM)
-1.4077
1D
5D
1M
3M
1Y
5Y
1D
Press Release: Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025
Dow Jones · 13h ago
Noteworthy Monday Option Activity: SOFI, SPOT, OMER
NASDAQ · 16h ago
Omeros Restructures $80.5M In Debt With New Notes And Stock Conversion Agreements
NASDAQ · 17h ago
Omeros Shares Drop After Notes Conversions
Dow Jones · 18h ago
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 18h ago
Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025
Barchart · 19h ago
*Omeros in Agreement With Investor to Convert $10 M of 2026 Convertible Notes Into Shrs >OMER
Dow Jones · 21h ago
Omeros trading resumes
TipRanks · 21h ago
More
About OMER
More
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Company’s lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
Recently
Symbol
Price
%Change

Webull offers Omeros Corp stock information, including NASDAQ: OMER real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OMER stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OMER stock methods without spending real money on the virtual paper trading platform.